• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

滤泡性淋巴瘤患者持续性 SARS-CoV-2 感染的管理。

Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma.

机构信息

Department of Hematology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

Department of Hematology, Hospital Universitario Fundación Alcorcón, Madrid, Spain,

出版信息

Acta Haematol. 2022;145(4):384-393. doi: 10.1159/000521121. Epub 2021 Nov 26.

DOI:10.1159/000521121
PMID:34839289
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9059018/
Abstract

INTRODUCTION

There is no consensus on the management of the coronavirus disease (COVID-19) in patients with secondary immunosuppression due to either an underlying hematological disease or to the effects of immunochemotherapy (ICT). Some of them may present persistent infection with multiple relapses of COVID-19, requiring several admissions. This study evaluated the clinical characteristics and outcomes after treatment of 5 patients with follicular lymphoma (FL), previously treated with ICT, who developed several episodes of COVID-19.

METHODS

We analyzed the clinical evolution and response to treatment with antiviral agent, steroids, and convalescent plasma in 5 patients with FL and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persistent infection. Reverse transcriptase polymerase chain reaction tests and peripheral blood immunophenotype were performed for all patients.

RESULTS

All patients required hospitalization due to pneumonia with severity criteria and were re-admitted after a median of 22 days (13-42) from the previous discharge. They all showed B-cell depletion by immunophenotyping, and no traces of immunoglobulin antibodies against SARS-CoV-2 were detected in any of the cases. The survival rate was 80%.

CONCLUSION

The combination therapy evidenced clinical benefits, demonstrating its capacity to control infection in immunosuppressed FL patients treated with ICT.

摘要

简介

由于潜在的血液系统疾病或免疫化学疗法 (ICT) 的影响而导致继发性免疫抑制的 COVID-19 患者的管理尚无共识。他们中的一些人可能会持续感染 COVID-19 并多次复发,需要多次住院治疗。本研究评估了 5 例先前接受 ICT 治疗的滤泡性淋巴瘤 (FL) 患者发生多次 COVID-19 后治疗的临床特征和结局。

方法

我们分析了 5 例 FL 伴严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 持续感染患者的抗病毒药物、类固醇和恢复期血浆治疗的临床演变和反应。对所有患者均进行逆转录酶聚合酶链反应检测和外周血免疫表型分析。

结果

所有患者均因肺炎伴有严重程度标准而需要住院治疗,在前一次出院后中位数为 22 天(13-42 天)再次入院。免疫表型分析显示所有患者均出现 B 细胞耗竭,且在任何情况下均未检测到针对 SARS-CoV-2 的免疫球蛋白抗体。存活率为 80%。

结论

联合治疗显示出临床获益,证明其能够控制接受 ICT 治疗的免疫抑制性 FL 患者的感染。

相似文献

1
Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma.滤泡性淋巴瘤患者持续性 SARS-CoV-2 感染的管理。
Acta Haematol. 2022;145(4):384-393. doi: 10.1159/000521121. Epub 2021 Nov 26.
2
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染:使用 casirivimab 和 imdevimab(REGN-COV2)单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.
3
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
4
Persistent COVID-19: A Case Report of an Immunocompromised Patient and a Literature Review.持续性新冠病毒感染:一例免疫功能低下患者的病例报告及文献综述
Acta Haematol. 2024;147(5):571-575. doi: 10.1159/000537793. Epub 2024 Feb 15.
5
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.治疗或预防 SARS-CoV-2 感染延长和严重阶段的 B 细胞耗竭剂的临床管理:定义治疗途径。
Front Immunol. 2022 May 27;13:911339. doi: 10.3389/fimmu.2022.911339. eCollection 2022.
6
A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.一名63岁有非霍奇金淋巴瘤病史且持续感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的女性,其血清学检测呈阴性,接受了恢复期血浆治疗。
Am J Case Rep. 2020 Oct 3;21:e927812. doi: 10.12659/AJCR.927812.
7
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
8
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验,比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效(RECOVER):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.
9
Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.两名免疫功能低下的持续性 COVID-19 感染者在抗体治疗后出现刺突突变的演变。
J Med Virol. 2022 Mar;94(3):1241-1245. doi: 10.1002/jmv.27445. Epub 2021 Nov 13.
10
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.新型冠状病毒对造血干细胞移植和嵌合抗原受体 T 细胞治疗受者的影响。
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.

引用本文的文献

1
Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.奈玛特韦-利托那韦治疗后新型冠状病毒2检测呈阳性患者的临床特征及治疗效果
J Med Virol. 2025 May;97(5):e70377. doi: 10.1002/jmv.70377.
2
Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study.应对滤泡性淋巴瘤中 COVID-19 大流行挑战的抗 CD20 维持策略:意大利多中心 R-FolSTOP 研究结果
Ann Hematol. 2025 Mar;104(3):1655-1667. doi: 10.1007/s00277-025-06295-0. Epub 2025 Mar 12.
3
Interstitial lung changes and persistent COVID-19 in a patient with follicular lymphoma: A case report.滤泡性淋巴瘤患者的间质性肺改变与持续性新型冠状病毒肺炎:一例报告
Respirol Case Rep. 2024 Feb 20;12(2):e01298. doi: 10.1002/rcr2.1298. eCollection 2024 Feb.
4
Clinical course and management of COVID-19 in the era of widespread population immunity.广泛人群免疫时代下的 COVID-19 临床病程和管理。
Nat Rev Microbiol. 2024 Feb;22(2):75-88. doi: 10.1038/s41579-023-01001-1. Epub 2023 Dec 19.
5
Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series.在奥密克戎时代,序贯或联合治疗作为免疫功能低下的持续性严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染患者的挽救疗法:病例系列
Antibiotics (Basel). 2023 Sep 19;12(9):1460. doi: 10.3390/antibiotics12091460.
6
Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma.在一例接受恶性淋巴瘤B细胞清除免疫治疗后出现长时间新冠病毒感染的病例中,使用瑞德西韦和恩西他韦进行成功的双重抗病毒治疗。
IDCases. 2023 Aug 30;34:e01890. doi: 10.1016/j.idcr.2023.e01890. eCollection 2023.
7
Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment.滤泡性淋巴瘤患者在接受奥滨尤妥珠单抗治疗后出现持续性 SARS-CoV-2 感染和机化性肺炎:具有挑战性的识别和治疗。
Viruses. 2023 Mar 7;15(3):693. doi: 10.3390/v15030693.
8
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者:系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
9
The Cumulative Detrimental Effect of COVID-19 Pneumonia in a Patient with Myasthenic Crisis: A Case Report and Overview of the Literature.新型冠状病毒肺炎对重症肌无力危象患者的累积有害影响:一例病例报告及文献综述
Life (Basel). 2022 Sep 23;12(10):1482. doi: 10.3390/life12101482.

本文引用的文献

1
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.一项针对 COVID-19 肺炎住院患者的恢复期血浆的多中心随机开放标签临床试验。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI152740.
2
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.CAPSID 随机试验结果:高剂量恢复期血浆治疗重症 COVID-19 患者。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI152264.
3
Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.恢复期血浆与 COVID-19 住院患者的死亡率降低和临床病程改善相关。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI151788.
4
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.恢复期血浆疗法与血液系统恶性肿瘤合并 COVID-19 患者生存情况的关联
JAMA Oncol. 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799.
5
Use of convalescent plasma in COVID-19 patients with immunosuppression.COVID-19 免疫抑制患者使用恢复期血浆。
Transfusion. 2021 Aug;61(8):2503-2511. doi: 10.1111/trf.16525. Epub 2021 Jun 1.
6
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.接受B细胞耗竭免疫疗法治疗的非霍奇金淋巴瘤患者感染新冠病毒后住院时间延长且死亡率更高。
Am J Hematol. 2021 Aug 1;96(8):934-944. doi: 10.1002/ajh.26209. Epub 2021 May 12.
7
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection.免疫功能低下宿主中持续性严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)感染导致的严重临床复发
Leukemia. 2021 Mar;35(3):920-923. doi: 10.1038/s41375-021-01175-8. Epub 2021 Feb 19.
8
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study.淋巴瘤患者感染新型冠状病毒肺炎的危险因素及死亡率:一项多中心研究
Hemasphere. 2021 Feb 10;5(3):e538. doi: 10.1097/HS9.0000000000000538. eCollection 2021 Mar.
9
Evolution of antibody immunity to SARS-CoV-2.SARS-CoV-2 抗体免疫的演变。
Nature. 2021 Mar;591(7851):639-644. doi: 10.1038/s41586-021-03207-w. Epub 2021 Jan 18.
10
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.